Alnylam Pharma (ALNY) Misses Q3 EPS by 7c

November 2, 2016 4:02 PM EDT

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Alnylam Pharma (NASDAQ: ALNY) reported Q3 EPS of ($1.21), $0.07 worse than the analyst estimate of ($1.14). Revenue for the quarter came in at $13.7 million versus the consensus estimate of $9.14 million.

At September 30, 2016, Alnylam had cash, cash equivalents and marketable securities, and restricted investments of $1.19 billion, as compared to cash, cash equivalents and marketable securities of $1.28 billion at December 31, 2015.

For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories


Related Entities


Add Your Comment